Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis (Q36065744)

12 August 2017

1 reference

title

Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis (English)

1 reference

12 August 2017

Ashesh B Jani

1

1 reference

12 August 2017

Johnny Kao

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

103

1 reference

12 August 2017

1833-1842

1 reference

12 August 2017

9

1 reference

The number needed to treat: a clinically useful measure of treatment effect

12 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

Salvage radiation for a rising PSA following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

Prostate cancer epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Early prostate cancer: clinical decision-making

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Radiation therapy (RT) after prostatectomy: The case for salvage therapy as opposed to adjuvant therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

An assessment of clinically useful measures of the consequences of treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Number needed to treat (NNT)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Adjusting the number needed to treat: incorporating adjustments for the utility and timing of benefits and harms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

The application of number needed to treat (NNT) to clinical problems in radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

An evidence-based analysis of the management of localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Sentinel lymph node versus axillary lymph node dissection for early-stage breast carcinoma: a comparison using a utility-adjusted number needed to treat analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: the importance of radiation dose

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Postprostatectomy radiotherapy for high-risk prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Comparison of outcomes of radical prostatectomy with and without adjuvant pelvic irradiation in patients with pathologic stage C (T3N0) adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Adjuvant radiation therapy does not cause urinary incontinence after radical prostatectomy: results of a prospective randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Post-nerve-sparing prostatectomy, dose-escalated intensity-modulated radiotherapy: effect on erectile function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Intensity-modulated radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Quality-of-life-adjusted survival for comparing cancer treatments. A commentary on TWiST and Q-TWiST.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20949

7 January 2021

Identifiers

DOI

10.1002/CNCR.20949

1 reference

release_yuvzmmorr5ha5lrnhjbz6byv64

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yuvzmmorr5ha5lrnhjbz6byv64

24 November 2022

mapped directly with Wikidata item

1 reference